Meropenem CAS 96036-03-2
Meropenem is one kind of white or almost white crystalline powder.Besides, Meropenem belongs to Active Pharmaceutical Ingredients;Antibacterial;Cnbio;pharmaceutical intermediates. In addition, Meropenem Classification Code is Anti-Bacterial Agents; Anti-Infective Agents; Drug/Therapeutic Agent;Reproductive Effect. What's more, Meropenem is soluble in 5% monobasic potassium phosphate solution, sparingly soluble in water, very slightly soluble in hydrated ethanol.
Meropenem is an anti-infective drug for adults and children caused by a single or multiple meropenem sensitive bacteria. The first choice drug for severe nosocomial infection, mixed infection with G-bacteria, multi-drug-resistant bacteria and enzyme-producing bacteria. Pneumonia includes nosocomial pneumonia, urinary tract infections, gynaecological infections (such as endometritis and pelvic inflammatory disease), skin and soft tissue infections, meningitis, septicaemia.
Meropenem (CAS NO.96036-03-2) was originally developed by Sumitomo Pharmaceuticals. It is marketed outside Japan by AstraZeneca with the brand names Merrem and Meronem . Other brand names include Mepem (Taiwan) , Meropen (Japan, Korea) and Neopenem (India) . It gained FDA approval in July 1996. It penetrates well into many tissues and body fluids including the cerebrospinal fluid, bile, heart valves, lung, and peritoneal fluid.
Meropenem is a new carbapenem antibiotic introduced to market for the i.v. treatment of a wide variety of hospital infections such as lower respiratory tract, urinary tract, intraabdominal, gynecological and polymicrobial infections. Meropenem has a broad spectrum of antibacterial activity against most clinically important Gram-positive and Gramnegative aerobic and anaerobic bacteria with especially high potency against multiresistant Enterobacteriaceae and Pseudornonas aeruginosa. Compared with imipenem, the only other available carbapenem antibiotic, meropenem has the advantage of being dehydropeptidase 1 (DHP-1) stable and therefore does not need to be administered in conjunction with the DHP-1 inhibitor cilastatin. Meropenem is also being evaluated for treatment of resistant pseudomonal infections in cystic fibrosis patients.
